Open access
Sep 2026
A highly potent bispecific antibody confers complete protection against SFTSV in preclinical models.
Severe fever with thrombocytopenia syndrome virus (SFTSV) is an emerging bunyavirus that causes severe human disease, with a case fatality rate of up to 30%. However, no licensed therapeutics are currently available for clinical use. Here, we identified two SFTSV neutralizing nanobodies (Nbs), N2C1 and N2D2, which inhi...
Xiao-Ping Guo, Fu-Jian Wan, Wu-Jian Li et al.
· Proceedings of the National... · 0 citations